Effect of Chronic Inflammation on Myocardial Perfusion and Function

Overview

Background: Heart failure (HF) is a public health burden. Studies have shown a link between inflammation, myocardial dysfunction, and HF. Researchers want to use psoriasis as a disease model of chronic inflammation to further study the link between inflammation and myocardial dysfunction. Objective: To learn if chronic inflammation affects the heart and if taking a biological medicine for chronic inflammation helps improve how the heart works. Eligibility: Adults ages 18 and older who have moderate to severe psoriasis, and healthy adult volunteers. Design: Participants will be screened with a medical history. They may take a pregnancy test. Healthy volunteers will have 1 visit. Those with psoriasis will have a second visit 1 year later. Participants may give blood samples. They may have a heart function test. They may have a heart imaging test, and may get a contrast agent. If so, it will be injected into a vein. Participants may have positron emission tomography/computed tomography tests. They will lie on their back on a padded table with their arms straight overhead. They may get radioactive drugs through an intravenous (IV) catheter. They will get stress medicines through the IV. These drugs mimic exercise and increase blood flow through the heart. Participants may have cardiac magnetic resonance imaging. The scanner is a large tube. Participants will lie on a table that slides in and out of the tube. They will get gadolinium contrast in a vein to improve the pictures. They may get stress medicines. Coils will be used to help make the pictures. Participation for healthy volunteers will last 1-2 days. Participation for those with psoriasis will last 14 months.

Full Title of Study: “The Effect of Chronic Inflammation on Myocardial Perfusion and Function”

Study Type

  • Study Type: Observational
  • Study Design
    • Time Perspective: Prospective
  • Study Primary Completion Date: June 30, 2024

Detailed Description

Heart failure (HF) remains a significant public health burden despite expanding and improving treatment options. Clinical and pre-clinical studies have demonstrated compelling relationships between inflammation, myocardial dysfunction, HF and adverse clinical outcomes. In this study to be conducted at the NIH Clinical Center, we propose to utilize psoriasis as a disease model to study how chronic inflammation effects myocardial perfusion, measured by myocardial flow reserve (MFR) on positron emission tomography (PET) and cardiac MRI (CMR), and myocardial function and tissue composition measured by multi-modality cardiovascular imaging. Objectives: To test the hypothesis that chronic inflammation is a driver of perturbances in myocardial perfusion, function and tissue composition To test the hypothesis that biologic treatment for psoriasis will be associated with longitudinal improvement in myocardial perfusion, function and tissue composition To characterize immune cell subsets and their association with myocardial perfusion, function and tissue composition in chronic inflammation To explore how chronic inflammation may alter myocardial energetics and metabolism Endpoints: Primary outcomes will be: Myocardial perfusion, as assessed by myocardial flow reserve (MFR), in subjects with moderate to severe psoriasis compared to matched healthy controls. Secondary outcomes will be: Change in MFR in subjects with psoriasis on biologic therapy at 1 year follow-up compared to baseline. Diastolic function (on echocardiogram), myocardial mechanics (on echocardiogram and CMR), myocardial edema and inflammation, and interstitial fibrosis (on CMR) in subjects with moderate to severe psoriasis compared to matched healthy controls. Change in diastolic function, myocardial mechanics, myocardial edema and inflammation, and interstitial fibrosis in subjects with psoriasis on biologic therapy at 1 year follow- up

Arms, Groups and Cohorts

  • Affected Subjects
    • Subjects diagnosed with moderate- severe psoriasis
  • Healthy Controls
    • Females and males 18 years of age or older

Clinical Trial Outcome Measures

Primary Measures

  • Miocardial perfusion in affected vs healthy individuals
    • Time Frame: 1 day
    • Primary outcome will be: Myocardial perfusion, as assessed by myocardial flow reserve (MFR), in subjects with moderate to severe psoriasis compared to matched healthy controls.

Secondary Measures

  • Change in MFR in subjects on biologic therapy
    • Time Frame: 1 year
    • Change in MFR in subjects with psoriasis on biologic therapy at 1 year follow-up compared to baseline. 2.Diastolic function (on echocardiogram), myocardial mechanics (on echocardiogram and CMR), myocardial edema and inflammation, and interstitial fibrosis (on CMR) in subjects with moderate to severe psoriasis compared to matched healthy controls. 3.Change in diastolic function, myocardial mechanics, myocardial edema and inflammation, and interstitial fibrosis in subjects with psoriasis on biologic therapy at 1 year follow- up

Participating in This Clinical Trial

Inclusion Criteria

Subjects of both genders will be considered for inclusion in this study. There will be no racial, ethnic, or gender discrimination. Affected Subjects:

  • 18 years of age or older – Diagnosed with moderate-severe psoriasis clinically confirmed by licensed physician, or advanced practitioner consisting of typical skin findings and/or associated findings of systemic disease of joints, nails and hair and may be scheduled to initiate biologic treatment for psoriasis Healthy Controls: Females and males 18 years of age or older EXCLUSION CRITERIA:

Affected Subjects:

  • Pregnant or lactating women – Subjects with a contraindication to MRI scanning will not receive the CMR assessment. These contraindications include subjects with the following devices: i. Central nervous system aneurysm clips ii. Implanted neural stimulator iii. Implanted cardiac pacemaker or defibrillator iv. Cochlear implant v. Ocular foreign body (e.g. metal shavings) vi. Implanted Insulin pump vii. Metal shrapnel or bullet viii. Estimated glomerular filtration rate (eGFR) < 30 mL/min/1.73m^2 body surface area according to the Modification of Diet in Renal Disease criteria – History of seizures or taking anti-epileptic medications – Inability to provide informed consent Healthy Controls: – Diagnosis of an inflammatory disease (including psoriasis, psoriatic arthritis, rheumatoid arthritis, lupus, inflammatory bowel disease) – Pregnant women and lactating women – Subjects with a contraindication to MRI scanning will not receive the CMR assessment. These contraindications include subjects with the following devices: ix. Central nervous system aneurysm clips x. Implanted neural stimulator xi. Implanted cardiac pacemaker or defibrillator xii. Cochlear implant xiii. Ocular foreign body (e.g. metal shavings) xiv. Implanted Insulin pump xv. Metal shrapnel or bullet xvi. Estimated glomerular filtration rate (eGFR) < 30 mL/min/1.73m^2 body surface area according to the Modification of Diet in Renal Disease criteria – History of seizures or taking anti-epileptic medications – Inability to provide informed consent

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: Accepts Healthy Volunteers

Investigator Details

  • Lead Sponsor
    • National Heart, Lung, and Blood Institute (NHLBI)
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Wunan Y Zhou, M.D., Principal Investigator, National Heart, Lung, and Blood Institute (NHLBI)
  • Overall Contact(s)
    • Tania R Machado, (301) 661-1505, tania.machado@nih.gov

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.